Evaluation of pharmacogenetic markers to predict the risk of cisplatin-induced ototoxicity

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 2, 2014, Pages 156-157

  Lanvers Kaminsky, C ^a   Malath, I ^a   Deuster, D ^a   Ciarimboli, G ^a   Boos, J ^a   Am Zehnhoff Dinnesen, A G ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

COMT GENE; EVALUATION STUDY; GENE; GENETIC MARKER; GENETIC RISK; GENOTYPE; HUMAN; LETTER; NONHUMAN; OTOTOXICITY; PERCEPTION DEAFNESS; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TPMT GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; CISPLATIN; FEMALE; HEARING LOSS; HUMANS; MALE; METHYLTRANSFERASES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS;

EID: 84904855269     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.67     Document Type: Letter

References (5)

1. Yang, J.J. et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin. Pharmacol. Ther. 94, 252-259 (2013
2. Pussegoda, K. et al.; CPNDS Consortium Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin. Pharmacol. Ther. 94, 243-251 (2013
3. Boddy, A.V. Genetics of cisplatin ototoxicity: Confirming the unexplained? Clin. Pharmacol. Ther. 94, 198-200 (2013
4. Riedemann, L. et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J. 8, 23-28 (2008
5. Ross, C.J. et al.; CPNDS Consortium Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41, 1345-1349 (2009.